Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)
Journal
The American journal of gastroenterology
Journal Volume
115
Journal Issue
8
Pages
1226-1235
Date Issued
2020
Author(s)
Huang C.-F.
Lai H.-C.
Chen C.-Y.
Tseng K.-C.
Kuo H.-T.
Hung C.-H.
Wang J.-H.
Chen J.-J.
Lee P.-L.
Chien R.-N.
Yang C.-C.
Lo G.-H.
Tai C.-M.
Lin C.-W.
Yan S.-L.
Bair M.-J.
Lin C.-Y.
Su W.-W.
Chu C.-H.
Chen C.-J.
Tung S.-Y.
Lo C.-C.
Cheng P.-N.
Chiu Y.-C.
Wang C.-C.
Cheng J.-S.
Tsai W.-L.
Lin H.-C.
Huang Y.-H.
Yeh M.-L.
Huang J.-F.
Dai C.-Y.
Chuang W.-L.
Tsai P.-C.
Peng C.-Y.
Yu M.-L.
Abstract
INTRODUCTION: Chronic hepatitis C virus (HCV) infection is associated with nonhepatocellular carcinoma malignancies. We aimed to evaluate whether achieving a sustained virological response (SVR, defined as HCV RNA seronegativity throughout posttreatment 24-week follow-up) could reduce the risk of non-hepatocellular carcinoma malignancy in a real-world nationwide Taiwanese Chronic Hepatitis C Cohort (T-COACH). METHODS: A total of 10,714 patients with chronic hepatitis C who had received interferon-based therapy (8,186 SVR and 2,528 non-SVR) enrolled in T-COACH and were linked to the National Cancer Registry database for the development of 12 extrahepatic malignancies, including those with potential associations with HCV and with the top-ranking incidence in Taiwan, over a median follow-up period was 3.79 years (range, 0-16.44 years). RESULTS: During the 44,354 person-years of follow-up, 324 (3.02%) patients developed extrahepatic malignancies, without a difference between patients with and without SVR (annual incidence: 0.69% vs 0.87%, respectively). Compared with patients with SVR, patients without SVR had a significantly higher risk of gastric cancer (0.10% vs 0.03% per person-year, P = 0.004) and non-Hodgkin lymphoma (NHL) (0.08% vs 0.03% per person-year, respectively, P = 0.03). When considering death as a competing risk, non-SVR was independently associated with gastric cancer (hazard ratio [HR]/95% confidence intervals [CIs]: 3.29/1.37-7.93, P = 0.008). When patients were stratified by age, the effect of SVR in reducing gastric cancer (HR/CI: 0.30/0.11-0.83) and NHL (HR/CI: 0.28/0.09-0.85) was noted only in patients aged <65 years but not those aged >65 years. DISCUSSION: HCV eradication reduced the risk of gastric cancer and NHL, in particular among younger patients, indicating that patients with chronic hepatitis C should be treated as early as possible.
SDGs
Other Subjects
antivirus agent; age; aged; chronic hepatitis C; cohort analysis; female; human; incidence; male; middle aged; mortality; nonhodgkin lymphoma; register; stomach tumor; survival analysis; sustained virologic response; Taiwan; Age Factors; Aged; Antiviral Agents; Cohort Studies; Female; Hepatitis C, Chronic; Humans; Incidence; Lymphoma, Non-Hodgkin; Male; Middle Aged; Registries; Stomach Neoplasms; Survival Analysis; Sustained Virologic Response; Taiwan
Publisher
NLM (Medline)
Type
journal article